Ghosh, Nilasha

Publications

Sort by

Co-Author Network

selected publications

Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study. Annals of the rheumatic diseases. 2026 Academic Article GET IT
Arthroplasty Joint Histology and Surgical Outcomes in Patients on Immune Checkpoint Inhibitors: A Single-Center Case Series. The Journal of rheumatology. 2026 Article GET IT
Times cited: 1
Necrotizing and Nonnecrotizing Granulomatous Reactions in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Literature Review. The Journal of rheumatology. 2025 Information Resource GET IT
Times cited: 1
Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma. JCI insight. 2025 Academic Article GET IT
Times cited: 4
Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma. bioRxiv : the preprint server for biology. 2025 Article GET IT
Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis. Arthritis care & research. 2025 Academic Article GET IT
Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study. Rheumatology (Oxford, England). 2025 Academic Article GET IT
Times cited: 9
Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group. Seminars in arthritis and rheumatism. 2024 Academic Article GET IT
Times cited: 1
The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review. Rheumatic diseases clinics of North America. 2024 Information Resource GET IT
Times cited: 4
Evolving and evaluating the OMERACT fellows program: insights and implications from OMERACT 2023 fellows. Seminars in arthritis and rheumatism. 2024 Academic Article GET IT
Times cited: 1
Erratum to "2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective" [The Journal of Arthroplasty 38 (2023) 2193-2201]. The Journal of arthroplasty. 2023 Article GET IT
Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure. Rheumatology (Oxford, England). 2023 Academic Article GET IT
Times cited: 5
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective. The Journal of arthroplasty. 2023 Information Resource GET IT
Times cited: 23
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective. Arthritis care & research. 2023 Information Resource GET IT
Times cited: 39
2023 American College of Rheumatology and American Association of Hip and Knee Surgeons Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty for Patients With Symptomatic Moderate-to-Severe Osteoarthritis or Advanced Symptomatic Osteonecrosis With Secondary Arthritis for Whom Nonoperative Therapy Is Ineffective. Arthritis & rheumatology (Hoboken, N.J.). 2023 Information Resource GET IT
Times cited: 20
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 'shared epitope' are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis. RMD open. 2023 Academic Article GET IT
Times cited: 4
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Annals of the rheumatic diseases. 2023 Academic Article GET IT
Times cited: 68
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. Seminars in arthritis and rheumatism. 2022 Information Resource GET IT
Times cited: 15
Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2022 Information Resource GET IT
Times cited: 22
Rheumatic Complications of Immune Checkpoint Inhibitors. Rheumatic diseases clinics of North America. 2022 Information Resource GET IT
Times cited: 5
Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2022 Information Resource GET IT
Times cited: 60
Checkpoint Inhibitor-Associated Autoimmunity: What a Rheumatologist Needs to Know. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2022 Academic Article GET IT
Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 55
Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2021 Article GET IT
Times cited: 67
The Patients' Perspective of Important Glucocorticoid Effects: A Nominal Group Study Among Patients With Systemic Lupus Erythematosus and Myositis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2021 Academic Article GET IT
Times cited: 8
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. Seminars in arthritis and rheumatism. 2021 Academic Article GET IT
Times cited: 13
Rheumatic Complications of Immune Checkpoint Inhibitors. The Medical clinics of North America. 2021 Information Resource GET IT
Times cited: 7
Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. ACR open rheumatology. 2020 Academic Article GET IT
Times cited: 20
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 4
Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2020 Academic Article GET IT
Times cited: 1
Social Determinants of Health Training in U.S. Primary Care Residency Programs: A Scoping Review. Academic medicine : journal of the Association of American Medical Colleges. 2019 Information Resource GET IT
Times cited: 61
Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. Arthritis research & therapy. 2017 Information Resource GET IT
Times cited: 24
Moving beyond the limitations of the visual analog scale for measuring pain: novel use of the general labeled magnitude scale in a clinical setting. American journal of physical medicine & rehabilitation. 2014 Academic Article GET IT
Times cited: 33
A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Critical reviews in physical and rehabilitation medicine. 2013 Academic Article GET IT
Times cited: 197

more ...

less ...

Background

education and training

M.Sc., Weill Cornell Graduate School of Medical Sciences 2021
M.D., University of California, Irvine, School of Medicine 2015
B.A., Stanford University 2010

Contact

full name

Nilasha Ghosh

primary email

nig9070@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Nilasha Ghosh Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage